The effect of Cymbopogon citratus oil on treatment of endometriosis

The effect of vaginal preparation from Cymbopogon citratus oil on pain of patients with endometrioma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191207045636N1

Enrollment

Registered

2022-01-27

Start date

2022-02-19

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis. Endometriosis

Interventions

Intervention group: In this group, participants received a vaginal cream containing Cymbopogon citratus oil once a night Vaginally and They use special applicators. The drug is used during two purity

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Married women 20 to 50 years with pelvic pain and endometrioma Consent to participate in the project

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Acute and serious liver and kidney disease Pap smear with intraepithelial pathology changes Previous or treated malignancy

Design outcomes

Primary

Measure	Time frame
Pain score in the first 5 days of menstruation based on Visual Analouge scale(VAS) from 3 to 10. Timepoint: First in the first 5 days of menstrual bleeding before intervention, Then the first 5 days of menstrual bleeding after a period of medication for 20 days and for the third time in the first 5 days of menstrual bleeding after the second dose of the drug for 20 days. (In other words, once before taking the medicine, Once 4 weeks later and will be in the middle of the study and once after 8 weeks and at the end of the study.). Method of measurement: Measuring pain scale(Visual Analouge Scale).	—

Measure

Time frame

Pain score in the first 5 days of menstruation based on Visual Analouge scale(VAS) from 3 to 10. Timepoint: First in the first 5 days of menstrual bleeding before intervention, Then the first 5 days of menstrual bleeding after a period of medication for 20 days and for the third time in the first 5 days of menstrual bleeding after the second dose of the drug for 20 days. (In other words, once before taking the medicine, Once 4 weeks later and will be in the middle of the study and once after 8 weeks and at the end of the study.). Method of measurement: Measuring pain scale(Visual Analouge Scale).

—

Secondary

Measure	Time frame
Quality of life score based on endometriosis quality of life questionnaire. Timepoint: Beginning of study(before intervention) and 8 weeks later(end of intervention). Method of measurement: Endometriosis Quality of Life Questionnaire.;Ovarian cyst size based on unit of measurement mm (Cyst larger than 20 mm). Timepoint: Beginning of study(before intervention) and 8 weeks later(end of intervention). Method of measurement: Vaginal Sonography.;Gram-based analgesic consumption. Timepoint: Beginning of study(before intervention) and 8 weeks later(end of intervention). Method of measurement: Ask the patient.	—

Measure

Time frame

Quality of life score based on endometriosis quality of life questionnaire. Timepoint: Beginning of study(before intervention) and 8 weeks later(end of intervention). Method of measurement: Endometriosis Quality of Life Questionnaire.;Ovarian cyst size based on unit of measurement mm (Cyst larger than 20 mm). Timepoint: Beginning of study(before intervention) and 8 weeks later(end of intervention). Method of measurement: Vaginal Sonography.;Gram-based analgesic consumption. Timepoint: Beginning of study(before intervention) and 8 weeks later(end of intervention). Method of measurement: Ask the patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Yazdankhah

Shahid Beheshti University of Medical Sciences

zahrayazdankhah@sbmu.ac.ir+98 21 8877 3521

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026